Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Schöffski, Patrick; Chawla, Sant P; Maki, Robert G; Italiano, Antoine; Gelderblom, Hans; Choy, Edwin; Grignani, Giovanni; Camargo, Veridiana P.; Bauer, Sebastian; Rha, Sun Young; Blay, Jean-Yves; Hohenberger, Peter; D’Adamo, David; Guo, Matthew; Chmielowski, Bartosz; Le Cesne, Axel; Demetri, George D; Patel, Shreyaskumar R.

doi:10.1016/S0140-6736(15)01283-0

ScienceOpen: research and publishing network

For Publishers

For Researchers

Blog
About

Search
Advanced search

views

recommends

Record: found
Abstract: found
Article: not found

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Author(s): Patrick Schöffski, Sant P Chawla, Robert G Maki, Antoine Italiano, Hans Gelderblom, Edwin Choy, Giovanni Grignani, Veridiana P. Camargo, Sebastian Bauer, Sun Rha, Jean-Yves Blay, Peter Hohenberger, David D’Adamo, Matthew Guo, Bartosz Chmielowski, Axel Le Cesne, George Demetri, Shreyaskumar Patel

Publication date: 2016-04-16

Journal: Lancet (London, England)

Publisher: Elsevier BV

Read this article at

ScienceOpenPublisher PubMed

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

A non-randomised, phase 2 study showed activity and tolerability of eribulin in advanced or metastatic soft-tissue sarcoma. In this phase 3 study, we aimed to compare overall survival in patients with advanced or metastatic soft-tissue sarcoma who received eribulin with that in patients who received dacarbazine (an active control).